NCT03333343 2026-01-16
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
Novartis
Phase 1 Active not recruiting
Clinical Trials
8 trialsNCT01324479 2020-12-19
Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT01546428 2020-12-19
A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT02474537 2020-12-10
INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function
Novartis
Phase 1 Completed
NCT02520752 2020-12-10
A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT02626234 2020-12-10
A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT02205398 2019-01-22
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
Novartis
Phase 1 Terminated
NCT01072266 2017-11-22
A Dose-escalation Study in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1 Completed